After a string of pipeline deals aimed at revitalizing the R&D group, the decidedly private German company is undergoing a high-level makeover of the top team.
AMAL’s lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.
German pharma Boehringer Ingelheim is putting a few hundred million euros on the table to snap up Swiss cancer biotech Amal Therapeutics.